Analytical performance of the Synchron LX®20 Pro, BN™II and IMMAGE® high sensitivity C-reactive protein assays and concordance in cardiovascular risk stratification

2004 ◽  
Vol 347 (1-2) ◽  
pp. 71-79 ◽  
Author(s):  
Valerie C McWhorter ◽  
Lynne C Ford ◽  
Anthony W Butch
Keyword(s):  
Cardiovascular Risk ◽  
Risk Stratification ◽  
High Sensitivity ◽  
Analytical Performance ◽  
C Reactive Protein ◽  
Cardiovascular Risk Stratification ◽  
Reactive Protein ◽  
Protein Assays

Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay

2006 ◽  
Vol 44 (2) ◽  
Author(s):  
Snežana Jovičić ◽  
Svetlana Ignjatović ◽  
Marijana Dajak ◽  
Nada Majkić-Singh
Keyword(s):  
Cardiovascular Risk ◽  
Clinical Efficacy ◽  
Risk Estimation ◽  
High Sensitivity ◽  
Analytical Performance ◽  
C Reactive Protein ◽  
Cvd Risk ◽  
Reactive Protein ◽  
Deming Regression ◽  
Cardiovascular Risk Estimation

AbstractIncreased C-reactive protein (CRP) concentration within the reference interval (<10.0mg/L) is a strong predictor of cardiovascular disease (CVD) in apparently healthy adults. Cutoff points for use of CRP in estimating CVD risk are <1, 1–3 and >3mg/L for low, average and high relative risk, respectively. For measuring CRP concentrations to assess cardiovascular risk, high-sensitivity CRP (hsCRP) assays have been developed. The aim of this study was to evaluate the analytical performance and clinical efficacy for cardiovascular risk estimation of the Olympus immunoturbidimetric latex CRP assay (sensitive application). The comparative method used was the CardioPhase* hsCRP assay, approved by the Food and Drug Administration for use in CVD risk assessment. The imprecision of the Olympus hsCRP assay in the concentration range 0.2–10.0mg/L was 0.38–8.16% within runs and 3.75–9.63% between runs. For method comparison studies, 194 fresh serum samples were selected to cover the interval 0.15–10.0mg/L CRP. Comparison of the Dade Behring and Olympus methods was performed using weighted Deming regression analysis (slope 0.99mg/L, intercept 0.002mg/L, S

scholarly journals Evaluation of Turbidimetric High-Sensitivity C-Reactive Protein Assays for Cardiovascular Risk Estimation

2001 ◽  
Vol 47 (11) ◽  
pp. 2044-2046 ◽  
Author(s):  
Ahmad Hamwi ◽  
Thomas Vukovich ◽  
Oswald Wagner ◽  
Helmut Rumpold ◽  
Roswitha Spies ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Risk Estimation ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Protein Assays ◽  
Cardiovascular Risk Estimation

scholarly journals Improved Prognostic Value in Predicting Long-Term Cardiovascular Events by a Combination of High-Sensitivity C-Reactive Protein and Brachial–Ankle Pulse Wave Velocity

2021 ◽  
Vol 10 (15) ◽  
pp. 3291
Author(s):  
Hack-Lyoung Kim ◽  
Woo-Hyun Lim ◽  
Jae-Bin Seo ◽  
Sang-Hyun Kim ◽  
Joo-Hee Zo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Risk Stratification ◽  
Cardiovascular Events ◽  
Prognostic Value ◽  
Pulse Wave ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp

Background: Both C-reactive protein (CRP) and arterial stiffness are associated with the development of cardiovascular disease (CVD). This study was performed to investigate whether a combination of these two measurements could improve cardiovascular risk stratification. Methods: A total of 6572 consecutive subjects (mean age, 60.8 ± 11.8 years; female, 44.2%) who underwent both high-sensitivity CRP (hs-CRP) and brachial–ankle pulse wave velocity (baPWV) measurement within 1 week were retrospectively analyzed. Major adverse cardiovascular events (MACE), including cardiovascular death, acute myocardial infarction, coronary revascularization, and stroke were assessed during the clinical follow-up. Results: During a mean follow-up period of 3.75 years (interquartile range, 1.78–5.31 years), there were 182 cases of MACE (2.8%). The elevated baPWV (≥1505 cm/s) (hazard ratio (HR), 4.21; 95% confidence interval (CI), 2.73–6.48; p < 0.001) and hs-CRP (≥3 mg/L) (HR, 1.57; 95% CI, 1.12–2.21; p < 0.001) levels were associated with MACE even after controlling for potential confounders. The combination of baPWV and hs-CRP further stratified the subjects’ risk (subjects with low baPWV and hs-CRP vs. subjects with high baPWV and hs-CRP; HR, 7.08; 95% CI, 3.76−13.30; p < 0.001). Adding baPWV information to clinical factors and hs-CRP had an incremental prognostic value (global Chi-square score, from 126 to 167, p < 0.001). Conclusions: The combination of hs-CRP and baPWV provided a better prediction of future CVD than either one by itself. Taking these two simple measurements simultaneously is clinically useful in cardiovascular risk stratification.

Sign in / Sign up

Export Citation Format

Share Document